Sign In
Buy IDYA
$28.40
+0.530 (+1.90%)
At Close: Jun 03, 2026
Luminex Corp (DE) (LMNX) Q2 2020 Earnings Call Transcript | The Motley Fool
06:01am, Wednesday, 05'th Aug 2020
LMNX earnings call for the period ending June 30, 2020.
IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment
10:00am, Tuesday, 04'th Aug 2020
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced the effectiveness of the Collabora
QIAGEN Reports Full Results for Second Quarter and First Half Of 2020
12:00am, Tuesday, 04'th Aug 2020
QIAGEN reports full results for second quarter and first half of 2020
Biotech Bonanza - Second Half Outlook
08:24am, Tuesday, 28'th Jul 2020
Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest cre
$100.00 Million in Sales Expected for IDEAYA Biosciences (NASDAQ:IDYA) This Quarter
01:38am, Sunday, 19'th Jul 2020
Equities research analysts expect IDEAYA Biosciences (NASDAQ:IDYA) to post $100.00 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for IDEAYA Biosciences’
IDEAYA Biosciences (IDYA) Gets a Buy Rating from Oppenheimer - Markets
09:47am, Friday, 17'th Jul 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on IDEAYA Biosciences (IDYA – Research Report) today and set a price
IDEAYA Biosciences (IDYA) Receives a Buy from H.C. Wainwright - Markets
01:43pm, Thursday, 16'th Jul 2020
H.C. Wainwright analyst Edward White maintained a Buy rating on IDEAYA Biosciences (IDYA – Research Report) today and set a
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced that it has met the clinical prot
IDEAYA Biosciences (NASDAQ:IDYA) Upgraded to Buy by Zacks Investment Research
06:30pm, Wednesday, 15'th Jul 2020
IDEAYA Biosciences (NASDAQ:IDYA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, Zacks.com reports. The br
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced the Company will participate in t
Vaccine Makers BioNTech, Moderna, And Novavax Set To Run Higher
12:00am, Tuesday, 14'th Jul 2020
Stocks Analysis by Harry Boxer covering: KB Home, Vaxart Inc, Novavax Inc, Altimmune Inc. Read Harry Boxer's latest article on Investing.com
Osmotica's FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma
11:57am, Monday, 13'th Jul 2020
Osmotica gets FDA approval for Droopy Eyelid Treatment. NextCure advances solid tumor trial of NC410.
IDEAYA Biosciences (NASDAQ:IDYA) Upgraded to Overweight by JPMorgan Chase & Co.
07:08am, Monday, 13'th Jul 2020
IDEAYA Biosciences (NASDAQ:IDYA) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a note issued to investors on Monday, Briefing.com Automa
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib, a MEK Inhibitor
10:00am, Thursday, 09'th Jul 2020
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the Phas
The
